Arthritis drug may also work for rare eye disease

Image
IANS London
Last Updated : Oct 11 2016 | 1:07 PM IST

A well-known rheumatoid arthritis medication may be effective for treating non-infectious uveitis, a rare eye disease that can lead to loss of vision, new research has found.

Uveitis is the name used for inflammatory conditions of the inner eye, in particular the uvea, which consists of the iris and the ciliary body in the front section and the choroid in the back section. Inflammation can also affect other parts of the eye, such as the retina and the vitreous body.

"We were able to prospectively demonstrate for the very first time that non-infectious uveitis can also be successfully treated with a cortisol-free medication," said one of the researchers Talin Barisani-Asenbauer from Medical University of Vienna in Austria.

The biologic medication adalimumab has long been used to treat rheumatic diseases and has to be injected subcutaneously every two weeks.

For sufferers, steroid-free means there are fewer side-effects, so that it can be used over a longer period of time.

"That will significantly improve the management of uveitis patients who have only partially responded to corticosteroids, need a corticosteroid sparing therapy or who are unsuitable for treatment with corticosteroids," Barisani-Asenbauer explained.

The first symptoms of the disease are floaters in the visual field, blurred vision, visual disturbances and photosensitivity.

Potential complications of uveitis are macular oedema (accumulation of fluid in the retina), glaucoma or cataracts, for example. Uveitis can even lead to loss of vision.

The results of the multinational phase-three trial were published in the New England Journal of Medicine.

--IANS

gb/vm

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 11 2016 | 12:58 PM IST

Next Story